Jefferies Group's VRTX Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 31,372 shares of Vertex Pharmaceuticals Incorporated (VRTX) worth $14.22 M, representing 0.07% of the portfolio. First purchased in 2016-Q1, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in VRTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 38,814 shares. Largest reduction occurred in Q3 2024, reducing 27,632 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Vertex Pharmaceuticals Incorporated (VRTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Vertex Pharmaceuticals Incorporated (VRTX) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +15,372 | Add 96.08% | 31,372 | $453.36 |
| Q3 2025 | -18,615 | Reduce 53.78% | 16,000 | $391.64 |
| Q2 2025 | +15,131 | Add 77.66% | 34,615 | $445.20 |
| Q1 2025 | +5,500 | Add 39.33% | 19,484 | $484.82 |
| Q4 2024 | -18,659 | Reduce 57.16% | 13,984 | $402.70 |
| Q3 2024 | -27,632 | Reduce 45.84% | 32,643 | $465.08 |
| Q2 2024 | +3,453 | Add 6.08% | 60,275 | $468.72 |
| Q1 2024 | +38,814 | Add 215.54% | 56,822 | $418.01 |
| Q4 2023 | +17,707 | Add 5882.72% | 18,008 | $406.89 |
| Q3 2023 | -10,632 | Reduce 97.25% | 301 | $347.74 |
| Q2 2023 | -191 | Reduce 1.72% | 10,933 | $351.91 |
| Q1 2023 | +3,636 | Add 48.56% | 11,124 | $315.07 |
| Q4 2022 | +7,488 | New Buy | 7,488 | $288.78 |
| Q2 2016 | -3,300 | Sold Out | 0 | $0.00 |
| Q1 2016 | +3,300 | New Buy | 3,300 | $79.39 |
Jefferies Group's Vertex Pharmaceuticals Incorporated Investment FAQs
Jefferies Group first purchased Vertex Pharmaceuticals Incorporated (VRTX) in Q1 2016, acquiring 3,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Vertex Pharmaceuticals Incorporated (VRTX) for 15 quarters since Q1 2016.
Jefferies Group's largest addition to Vertex Pharmaceuticals Incorporated (VRTX) was in Q1 2024, adding 56,822 shares worth $23.75 M.
According to the latest 13F filing for Q4 2025, Jefferies Group's firm, Jefferies Financial Group Inc., owns 31,372 shares of Vertex Pharmaceuticals Incorporated (VRTX), valued at approximately $14.22 M.
As of the Q4 2025 filing, Vertex Pharmaceuticals Incorporated (VRTX) represents approximately 0.07% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Vertex Pharmaceuticals Incorporated (VRTX) was 60,275 shares, as reported at the end of Q2 2024.